Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes.
The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Hypoglycaemia is the limiting factor in the glycaemic management of diabetes. Iatrogenic hypoglycaemia is typically the result of the interplay of insulin excess and compromised glucose counterregulation in Type I (insulin-dependent) diabetes mellitus. Insulin concentrations do not decrease and glucagon and epinephrine concentrations do not increase normally as glucose concentrations decrease. The concept of hypoglycaemia-associated autonomic failure (HAAF) in Type I diabetes posits that recent antecedent iatrogenic hypoglycaemia causes both defective glucose counterregulation (by reducing the epinephrine response in the setting of an absent glucagon response) and hypoglycaemia unawareness (by reducing the autonomic and the resulting neurogenic symptom responses). Perhaps the most compelling support for HAAF is the finding that as little as 2 to 3 weeks of scrupulous avoidance of hypoglycaemia reverses hypoglycaemia unawareness and improves the reduced epinephrine component of defective glucose counterregulation in most affected patients. The mediator and mechanism of HAAF are not known but are under active investigation. The glucagon response to hypoglycaemia is also reduced in patients approaching the insulin deficient end of the spectrum of Type II (non-insulin-dependent) diabetes mellitus, and glycaemic thresholds for autonomic (including epinephrine) and symptomatic responses to hypoglycaemia are shifted to lower plasma glucose concentrations after hypoglycaemia in Type II diabetes. Thus, patients with advanced Type II diabetes are also at risk for HAAF. While it is possible to minimise the risk of hypoglycaemia by reducing risks -- including a 2 to 3 week period of scrupulous avoidance of hypoglycaemia in patients with hypoglycaemia unawareness -- methods that provide glucose-regulated insulin replacement or secretion are needed to eliminate hypoglycaemia and maintain euglycaemia over a lifetime of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of steady improvements in the glycemic management of diabetes, it is possible both to improve glycemic control and to minimize the risk of hypoglycemia in many patients (12, 16, 84 -86).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypoglycemia in diabetes is fundamentally the result of treatments that raise insulin levels and thus lower plasma glucose concentrations (12,16,84,85).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those treatments include insulin or insulin secretagogues such as a sulfonylurea or a nonsulfonylurea insulin secretagogue (e.g.nateglinide or repaglinide).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In type 1 diabetes, deficiency of the secretory response of glucagon to hypoglycemia is an early acquired abnormality of counterregulation.The catecholamine response compensates for several years but declines with time (1).”
From Hypoglycemia in Type 2 Diabetes (2005) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
From Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (2009) · cites this paper as [84]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Plum, F. (1960) · Archives of Neurology · doi:10.1001/archneur.1960.03840090124020 · Cited by 10,364
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059 · cited 2×
“Enough insulin, or any effective drug, to lower plasma glucose concentrations to or below the normal range would eliminate the symptoms of hyperglycaemia, prevent the acute hyperglycaemic complications (ketoacidosis, hyperosmolar syndrome), almost assuredly prevent the long-term microvascular complications [1, 2] and…”
BackgroundKhaw, K.-T. (2001) · BMJ · doi:10.1136/bmj.322.7277.15 · Cited by 1,017
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688 · cited 1×
“Finally, we and others have begun to study the mechanisms of the normal glucagon response to hypoglycaemia with the aim of gaining insight into the mechanism of the absence of the glucagon response in Type I diabetes [22], a critical component of defective glucose counterregulation and HAAF.”
BackgroundMitrakou, A., Ryan, C., Veneman, T., Mokan, M., Jenssen, T., Kiss, I., Durrant, J., Cryer, P., & Gerich, J. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.1.e67 · Cited by 558 · cited 2×
“0 mmol/l (54 mg/dl) respectively) are reproducible in healthy subjects [13, 14, 15], they shift to higher plasma glucose concentrations in poorly controlled diabetes [16, 17] and to lower plasma glucose concentrations following episodes of hypoglycaemia [18, 19, 20, 21].”
BackgroundSelf-citationHeller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Self-citation&NA; (1994) · Survey of Anesthesiology · doi:10.1097/00132586-199406000-00052 · Cited by 487
Dagogo-Jack, S. E., Craft, S., & Cryer, P. E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116302 · Cited by 471
Self-citation
Cited by
Items 501–600 of 793
Pedersen‐Bjergaard, U., Nielsen, S. L., Akram, K., Perrild, H., Nordestgaard, B. G., Montgomery, H., Pramming, S., & Thorsteinsson, B. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328331e67b · Cited by 11
Suthakaran, C., Anjana, R. M., Rao, K., Ranjit Unnikrishnan, I., Thangamani, S., & Mohan, V. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0066 · Cited by 10
“Iatrogenic hypoglycemia, due to interplay of insulin excess and compromised glucose counter regulation, is the major limiting factor in the management of glycemia in patients with type 1 and type 2 diabetes mellitus.(13) The use of CSII has been found to be associated with a significant decrease in rates of hypoglycem…”
Current literature in diabetes
Nazlıel, B., Yetkin, İ., İrkeç, C., & Koçer, B. (2001) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.173 · Cited by 10
Radziuk, J. (2012) · Diabetes · doi:10.2337/db12-0647 · Cited by 10
“As shown by the Diabetes Control and Complications Trial, tighter glucose control has been associated with an increased incidence of hypoglycemic episodes (1,11).”
MethodGlucagon – the new ‘insulin’ in the pathophysiology of diabetes
Farhy, L. S., & McCall, A. L. (2015) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000192 · Cited by 10
Messaaoui, A., Tenoutasse, S., Hajselova, L., & Crenier, L. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01297-x · Cited by 9
Carlsson, A., Forsander, G., Ludvigsson, J., Larsen, S., Örtqvist, E., & on behalf of the Swedish PREDICTIVE‐Youth Study Group (2013) · Pediatric Diabetes · doi:10.1111/pedi.12019 · Cited by 9
Oral contraception enhances growth hormone responsiveness to hyper‐ and hypoglycaemia
Friedrich, A., Ludwig, A. K., Jauch‐Chara, K., Loebig, M., Rudolf, S., Tauchert, S., Diedrich, K., Schweiger, U., & Oltmanns, K. M. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03430.x · Cited by 9
Fine-tuning therapy with basal insulin for optimal glycemic control in type 2 diabetes: a review
DAILEY, G. E. (2004) · Current Medical Research and Opinion · doi:10.1185/174234304x15183 · Cited by 10
Association of Basal Hyperglucagonemia with Impaired Glucagon Counterregulation in Type 1 Diabetes
Farhy, L. S., Chan, A., Breton, M. D., Anderson, S. M., Kovatchev, B. P., & McCall, A. L. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00040 · Cited by 12
“The abnormal GCR presents a major barrier to the safe treatment of the disease with intensive insulin therapy (Cryer, 1999, 2002; Segel et al., 2002) and even though extensively studied, the mechanism behind the GCR impairment remains unclear.”
BackgroundLes conséquences de l’hypoglycémie
Lachérade, J.-C., & Jacqueminet, S. (2009) · Annales Françaises d Anesthésie et de Réanimation · doi:10.1016/j.annfar.2009.02.037 · Cited by 14
Lobmann, R., & Lehnert, H. (2003) · Der Internist · doi:10.1007/s00108-003-1052-z · Cited by 19
Oktavian, P., Budi, D. S., Wibowo, I. N., Rusuldi, R. C. R., Kusumawardhani, A. D., Wafa, I. A., Rahman, H. R., Pratama, N. R., & Wibisono, S. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102847 · Cited by 8
Karamat, M. A., Dar, S., Bellary, S., & Tahrani, A. A. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0400-x · Cited by 9
“Insulin therapy is required to control BG levels in patients with T1D, but is associated with hypoglycemia, the major barrier to insulin titration and optimal glycemic control [23].”
BackgroundWang, J., Chen, H., Tang, F., & Sheu, W. H. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13485 · Cited by 9
Li, X., Wu, H., Huo, H., Ma, F., Zhao, M., Han, Q., Hu, L., Li, Y., Zhang, H., Pan, J., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120958 · Cited by 9
Physiological and Pathophysiological Control of Glucagon Secretion by Pancreatic α-Cells
Gilon, P., Cheng, R., Lai, B. K., Chae, H., & Gómez-Ruiz, A. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_37-2 · Cited by 9
Schreiber, S., & Russmann, A. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x80468 · Cited by 8
A Look at System-Wide Data Collection Processes to Improve Patient Outcomes
Malaskovitz, J., & Hodge, C. (2008) · Diabetes Spectrum · doi:10.2337/diaspect.21.4.262 · Cited by 8
Boada, C. A. C., & Martínez-Moreno, J. M. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6707 · Cited by 11
Ponzani, P., Berra, C., Lelio, A. D., Sindaco, P., Loreto, C. D., Reggiani, F., Lucisano, G., & Rossi, M. C. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00722-y · Cited by 8
Hypoglycaemia in Type 2 Diabetes and in Elderly People
Zammitt, N. N., & Frier, B. M. (2013) · Wiley eBooks · doi:10.1002/9781118695432.ch12 · Cited by 9
Ruiz-Pino, A., Goncalves-Ramírez, A., Jiménez-Palomares, M., Merino, B., Castellano-Muñoz, M., Vettorazzi, J. F., Rafacho, A., Marroquí, L., Nadal, Á., Alonso‐Magdalena, P., et al. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-03045-5 · Cited by 11
“Hyperglucagonemia, either absolute or relative to insulin levels, is associated in individuals with T2D with glucagon oversecretion in the non-fasted state and/or inadequate release of the hormone in the fasted state [13, 54].”
Ahammed, A., Pathan, F., Afsana, F., Ahammed, I., Mir, A. S., & Yusuf, A. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_338_17 · Cited by 7
“Apart from the distressing acute symptoms, hypoglycemia may also have a negative impact on the health of a patient with diabetes in the long term.[7] Another important aspect is the constant fear of developing hypoglycemia that some patients experience.”
BackgroundMohammadi, S. Z., Tajik, S., Tashakkorian, H., Zhang, K., Le, Q. V., Saeidi, S., Jang, H. W., Shokouhimehr, M., & Peng, W. (2020) · International Journal of Electrochemical Science · doi:10.20964/2020.09.49 · Cited by 7
Hoffman, E. G., D’Souza, N. C., Aiken, J., ATHERLEY, S. C., Liggins, R., & Riddell, M. C. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15002 · Cited by 9
“In type 1 diabetes (T1D), the counterregulatory glucagon response is typically absent within a few years of diagnosis, predisposing affected individuals to insulin-induced hypoglycaemia.(2) While the natural history of this acquired α-cell defect is not well characterized in type 2 diabetes (T2D), owing, at least in p…”
BackgroundThe Case for: Hypoglycemia Is of Cardiovascular Importance
Lalic, N. M. (2013) · Diabetes Care · doi:10.2337/dcs13-2016 · Cited by 8
Schouwenberg, B. J. J. W., Smits, P., Tack, C. J., & de Galan, B. E. (2011) · Diabetologia · doi:10.1007/s00125-011-2062-3 · Cited by 13
Yuan, G., Jia, J., Zhang, C., Yu, S., Dong, S., Ye, J., Zhu, T., Tang, B., Qian, W., Wang, D., et al. (2014) · Endocrine Journal · doi:10.1507/endocrj.ej13-0483 · Cited by 8
Spollett, G. R. (2012) · Diabetes Spectrum · doi:10.2337/diaspect.25.2.117 · Cited by 7
Tip 2 Diyabetes Mellituslu Bireylerin Hipoglisemi Korkusunun İncelenmesi
Gül, Ş., Aşiret, G. D., & OKATAN, C. (2021) · Etkili Hemşirelik Dergisi · doi:10.46483/deuhfed.825712 · Cited by 10
Schwab, K., Menche, U., Schmeisl, G., & Lohse, M. J. (2004) · Hormone Research in Paediatrics · doi:10.1159/000080064 · Cited by 12
Controversies in Treating Diabetes: Clinical and Research Aspects
LeRoith, D., & Vinik, A. I. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-572-5 · Cited by 11
Farhy, L. S., & McCall, A. L. (2009) · Journal of Diabetes Science and Technology · doi:10.1177/193229680900300104 · Cited by 7
Mathieu, C., Cuddihy, R. M., Arakaki, R. F., Belin, R. M., Planquois, J.-M., Lyons, J. N., & Heilmann, C. R. (2009) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0036 · Cited by 7
Adropin Is Expressed in Pancreatic Islet Cells and Reduces Glucagon Release in Diabetes Mellitus
Ali, I. I., D’Souza, C. M., Tariq, S., & Adeghate, E. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189824 · Cited by 7
“…in the percentage of α -cells in adropin-treated diabetic rats, and our immunoelectron microscopy results also revealed a decrease in the percentage of granules containing adropin and glucagon in that same animal group, suggesting the ability of adropin to regulate glucagon secretion in diabetes.”
ResultWendel, C., Fotieo, G. G., Shah, J. H., Felicetta, J. V., Curtis, B., & Murata, G. H. (2014) · Diabetic Medicine · doi:10.1111/dme.12543 · Cited by 6
Handling Exercise During Closed Loop Control
Breton, M. D. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0191 · Cited by 6
“Exercise has also been shown to mask hypoglycemic symptoms, thereby facilitating repeated exposure to unrecognized hypoglycemia and potentially causing hypoglycemia-associated autonomic failure(8) with all its negative consequences.(1) As a consequence, many people with T1DM engage in less exercise than their nondiabe…”
GSH-Independent Induction of ER Stress during Hypoglycaemia in the Retinal Cells of Mice
Fresia, D., Cannizzaro, E., Borgo, A., & Roduit, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112529 · Cited by 6
“Hypoglycaemia is not to be ignored for diabetic patients, with the average type 1 diabetic patient estimated to suffer two episodes of symptomatic hypoglycaemia per week, leading to thousands of such episodes over a lifetime, and at least one episode of severe hypoglycaemia per year [31].”
BackgroundRatzki‐Leewing, A. A., Black, J. E., Ryan, B. L., Zou, G., Klar, N. S., Webster-Bogaert, S., Timcevska, K., & Harris, S. B. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15186 · Cited by 7
“For people with insulin and/or secretagogue-treated diabetes, the trade-off between allaying long-term complications versus incurring the harms of hypoglycaemia can impede efforts to achieve glycaemic control.(50) Practice guidelines and initiatives emphasize the importance of reducing SH; however, even with the advan…”
BackgroundOvercoming barriers to technology in special groups
Alshatti, A., & Bishop, K. (2023) · Practical Diabetes · doi:10.1002/pdi.2478 · Cited by 6
Pīrāgs, V., El‐Damasy, H., Dąbrowski, M., Gönen, M. S., Račická, E., Martinka, E., Giaconia, J. M., Stefański, A., & On Behalf of the B001 Study Investigators (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2012.03001.x · Cited by 6
Role of histamine H3receptor in glucagon‐secreting αTC1.6 cells
Nakamura, T., Yoshikawa, T., Naganuma, F., Mohsen, A. S., Iida, T., Miura, Y., Sugawara, A., & Yanai, K. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.12.001 · Cited by 7
“Conversely, glucagon secretion is insufficient in response to critical hypoglycemia [10].”
BackgroundJiang, H. H., Ni, X., Huster, W. J., & Heilmann, C. R. (2014) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2014.919939 · Cited by 6
“Hypoglycemia has long been recognized as a major barrier to achieving normoglycemia with intensive diabetic therapies, especially for insulin treatment (Cryer, 2002; Korytkowski, 2002).”
BackgroundFarngren, J., Persson, M., & Åhrén, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13316 · Cited by 7
“The assays of total GIP and GLP-1 are C-terminally directed assays that cross-react to 100% with GIP (1-42), GIP (3-42), GLP-1 (7-36) and GLP-1 (9-36), respectively, whereas the assays of intact GIP and GLP-1 are N-terminally directed assays that require an intact N-terminal of GIP and GLP-1, respectively.”
MethodIbrahima, M. S. A., Attakpa, E., Justin, B. G., Amoussa, A. M. O., Sangare, M. M., Akotegnon, A. R., Guinnin, F. F. D., Lagnika, L., Sezan, A., Lamine, B.-M., et al. (2018) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2018/45640 · Cited by 6
Philis‐Tsimikas, A., Lane, W. S., Pedersen‐Bjergaard, U., Wysham, C., Bardtrum, L., Østoft, S. H., & Heller, S. R. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13954 · Cited by 7
Luo, J., Qu, Y., Zhang, Q., Chang, A. M., & Jacober, S. J. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817736315 · Cited by 186
Parker, D. R., Braatvedt, G. D., Bargiota, Α., Newrick, P. G., Brown, S., Gamble, G. D., & Corrall, R. J. M. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03173.x · Cited by 7
Breton, M. D., Clarke, W. L., Farhy, L. S., & Kovatchev, B. P. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100304 · Cited by 7
Cardoso, C., & de Arellano, A. R. (2016) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000653 · Cited by 5
“Although NSHs are easier to manage, they are more frequent than severe events and represent a major management problem in diabetes patients [8].”
BackgroundMata‐Cases, M. (2013) · Avances en Diabetología · doi:10.1016/j.avdiab.2013.07.002 · Cited by 5
Taub, M. B., Peyser, T. A., & Rosenquist, J. E. (2007) · Journal of Diabetes Science and Technology · doi:10.1177/193229680700100512 · Cited by 5
Is treatment with liraglutide efficient?
Raya, P. M., & Reyes‐García, R. (2014) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2014.03.003 · Cited by 5
Acute Diabetic Emergencies, Hypoglycemia, and Glycemic Control
Chansky, M. E., & Haddad, G. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50061-3 · Cited by 6
Pardo, S. A., Shaginian, R. M., & Simmons, D. A. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818762509 · Cited by 5
Hypoglycemia and Hypoglycemic Syndromes
Davis, S. N., Lamos, E. M., & Younk, L. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00047-0 · Cited by 5
Jódar, E., Romera, I., Wang, Q., Roche, S. L., & García‐Pérez, L. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14615 · Cited by 5
“control of diabetes due to the nature of treatment strategies to lower blood glucose levels.(3) This matter is complicated further by GV, which prompts the concern that the risk of hypoglycaemia as”
BackgroundAlassaf, A. A., Gharaibeh, L. F., Ibrahim, S., Alkhalaileh, S., & Odeh, R. (2023) · Pediatric Diabetes · doi:10.1155/2023/7258136 · Cited by 6
“Hypoglycemia is an important issue in T1D management, as the fear of its drastic consequences might prevent some families from giving the appropriate doses of insulin, with subsequent suboptimal glycemic control [37].”
Singh, A. K., Talwalkar, P., Ahluwalia, A. I., Modi, K. D., & Saboo, B. (2018) · PubMed · Cited by 5
Telliam, C., & Thivolet, C. H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.05.010 · Cited by 6
Pedersen‐Bjergaard, U. (2009) · PubMed · Cited by 7
Pallayová, M., & Breznoščáková, D. (2020) · Endocrine Regulations · doi:10.2478/enr-2020-0015 · Cited by 5
“…from the American Diabetes Association Workgroup on Hypoglycemia,” 2005; Seaquist et al. 2013) is often characteristic, the combination of deficient glucagon and epinephrine responses particularly in the individuals with long-standing T1DM causes defective glucose counterregulation (Cryer 2002).”
BackgroundFox, C. S. (2012) · Circulation · doi:10.1161/circulationaha.112.152777 · Cited by 5
Kulzer, B., Krichbaum, M., & Hermanns, N. (2013) · Der Diabetologe · doi:10.1007/s11428-012-0912-3 · Cited by 4
Plavšić, L., Mitrović, K., Todorovic, S., Vuković, R., Milenković, T., & Zdravković, D. (2014) · Vojnosanitetski pregled · doi:10.2298/vsp130422039p · Cited by 4
¿Es eficiente el tratamiento con liraglutida?
Raya, P. M., & Reyes‐García, R. (2013) · Endocrinología y Nutrición · doi:10.1016/j.endonu.2013.09.001 · Cited by 4
Moscardó, V., Rossetti, P., Ampudia‐Blasco, F. J., & Bondía, J. (2015) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2015.10.141 · Cited by 5
Fabris, C., Farhy, L. S., Anderson, S. M., Nass, R. M., Kovatchev, B. P., & Breton, M. D. (2017) · Journal of Diabetes Science and Technology · doi:10.1177/1932296817729392 · Cited by 4
“Consequently, patients with T1D face a lifelong optimization problem: to maintain a strict glycemic control without increasing the risk for hypoglycemia, which has been indeed identified as the major barrier to optimal diabetes management.(4) Hypoglycemia in T1D is typically the effect of the interplay of excessive in…”
BackgroundAutomated Adaptation of Insulin Treatment in Type 1 Diabetes
Fabris, C., Gautier, T., & Breton, M. D. (2021) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc46164.2021.9630191 · Cited by 7
“However, insulin therapies are not as efficient as the natural endogenous insulin secretion, and suboptimal insulin dosing is still common in the management of T1D, causing potentially life-threatening hypoglycemic episodes [12],[13] and/or sustained hyperglycemia which in turn leads to the development and progression…”
BackgroundKesavadev, J., Murthy, L. S., Chaudhury, T., Yalamanchi, S. R., Giri, J., Gupta, S., Phatak, S., Modi, K. D., Chatterjee, S., Manjunath, A., et al. (2022) · Metabolism Open · doi:10.1016/j.metop.2022.100184 · Cited by 4
“Risk of hypoglycemia poses a challenge to the willingness of physicians and patients to increase the insulin dose and thus leads to ineffective glycemic control [5].”
BackgroundScherbaum, W. A., & Scherbaum, C. R. (2014) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-013-0334-z · Cited by 6
A bright future for glucagon and alpha cell biology
Panzer, J. K., & Caicedo, A. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0315 · Cited by 5
Position statement of the SEMI, SED, redGDPS, SEC, SEEDO, SEEN, SEMERGEN y SEMFYC
Huelgas, R. G., Peralta, F. G., Fernández, L. C., Galve, E., Casanueva, F. F., Puig‐Domingo, M., Bravo, J. J. M., Beltrán, D. O., Muñoz, J. E., Torre, E. L. M., et al. (2015) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2015.09.004 · Cited by 5
Avari, P., Ramli, R., Reddy, M., Oliver, N. S., & Fothergill, R. T. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0439-3 · Cited by 4
Unnikrishnan, A., Saboo, B., Joshi, S., Kesavadev, J., Makkar, B. M., Agarwal, S., Aravind, S. R., Seshadri, K., Chawla, M. S., Deshpande, N., et al. (2019) · PubMed · Cited by 7
Pancreas anatomy and surgical procedure for pancreatectomy in rhesus monkeys
Zhang, Y., Fu, L., Lu, Y., Guo, Z., Zhang, Z.-D., Cheng, J.-Q., Hu, W.-M., Liu, X.-B., Mai, G., Zeng, Y., et al. (2011) · Journal of Medical Primatology · doi:10.1111/j.1600-0684.2011.00499.x · Cited by 4
Diabetes Technology and Treatment in the Pediatric Age Group
Shalitin, S., & Chase, H. P. (2013) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2013.1512 · Cited by 4
A robust microfluidic in vitro cell perifusion system
Morris, C., Banks, D., Gaweda, L., Scott, S., Zhu, X. X., Panico, M., Georgiou, P., & Toumazou, C. (2011) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/iembs.2011.6092075 · Cited by 4
“The role of glucagon in the prevention of low blood sugar (hypoglycemia) is prevalent in diabetic control research [5, 6].”
BackgroundNutritional Concerns in the Diabetic Athlete
Jensen, J. (2004) · Current Sports Medicine Reports · doi:10.1249/00149619-200408000-00004 · Cited by 5
Robust Tight Glycaemic Control of ICU patients
Kovács, L., Szalay, P., Benyó, B. I., & Chase, J. G. (2011) · IFAC Proceedings Volumes · doi:10.3182/20110828-6-it-1002.02852 · Cited by 4
“Moreover, with respect to the safety of glucose control, hypoglycaemia is the relevant parameter (Pachler et al. (2008), Cryer (2002)).”
BackgroundInsulin glargine in type 2 diabetes in everyday clinical practice: 7 years experience
Schreiber, S. A. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00842.x · Cited by 4
Muhammad, H. L., Busari, M. B., Okonkwo, U., & Abdullah, A. S. (2015) · Journal of Pharmaceutical Research International · doi:10.9734/bjpr/2015/15728 · Cited by 4
Cognitive Decline and Diabetes
Barbieri, M., Boccardi, V., & Paolisso, G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00035-5 · Cited by 4
Fredheim, S., Foli-Andersen, P. J., Lærkholm, G., Svensson, J., Juhl, C. B., Olsen, B. S., Pilgaard, K. A., & Johannesen, J. (2018) · Acta Paediatrica · doi:10.1111/apa.14310 · Cited by 4
“response to hypoglycaemia at night during sleep was a normal phenomenon or a long-term result of nocturnal hypoglycaemia in our type 1 diabetes patient group is to our knowledge unknown (22,23).”
BackgroundBiosynthesis, Secretion, and Action of Glucagon
Lefèbvre, P. J. (2003) · Wiley eBooks · doi:10.1002/0470862092.d0208 · Cited by 4
Kieu, A., Govender, R. D., Östlundh, L., & King, J. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-050027 · Cited by 3
Internalization and localization of basal insulin peglispro in cells
Moyers, J. S., Volk, C. B., Cao, J. X. C., Zhang, C., Ding, L., Kiselyov, V. V., & Michael, M. D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.032 · Cited by 3
Metabolic Disturbances: Hypo- and Hyperglycemic Seizures In Vivo and In Vitro a
Carlen, P. L., & Zhang, L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804066-9.00064-x · Cited by 3
Ponomareva, E., Schmerold, L. M., Srinivas, S. S. S., Preblick, R., Park, S., Wilson, L., & Revel, A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2277058 · Cited by 3
“Hypoglycemia is a frequent and potentially fatal adverse effect of insulins and some oral antidiabetic drugs (OADs) in patients with diabetes 11,12 .”
BackgroundOrozco‐Beltrán, D., López‐Pineda, A., Quesada, J. A., Artime, E., Díaz‐Cerezo, S., Redondo‐Antón, J., Santos, M. R., Spaepen, E., & Carratalá‐Munuera, C. (2023) · Primary care diabetes · doi:10.1016/j.pcd.2023.11.007 · Cited by 4
Ganji, M., Koravi, L. K. C., Breton, M. D., & Fabris, C. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251359641 · Cited by 3
Chan, W. B., Luk, A. O. Y., Chow, W. S., & Yeung, M. W. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12515 · Cited by 4
“These patients in particular may benefit from additional measures to address PPG excursions, which are not controlled by basal insulin.(3,9,10) Ultimately, many patients will require treatment with combination injectable therapy.”
Backgroundγ-Hydroxybutyrate does not mediate glucose inhibition of glucagon secretion
Yu, Q., Lai, B. K., Ahooghalandari, P., Helander, A., Gylfe, E., Gilon, P., & Tengholm, A. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009577 · Cited by 3
“This critical counter-regulatory action is often impaired in diabetes (1).”
BackgroundRees, T. M., Curtis, B. H., Gaskins, K. A., Sierra‐Johnson, J., Jiang, H. H., Liu, R., & Holcombe, J. H. (2013) · Endocrine Practice · doi:10.4158/ep13301.or · Cited by 3
Les conséquences de l’hypoglycémie
Lachérade, J.-C. (2008) · Réanimation · doi:10.1016/j.reaurg.2008.04.001 · Cited by 3
Managing hypoglycemia in children: what the clinician needs to know before advising parents
Ly, T. T., & Jones, T. W. (2012) · Diabetes Management · doi:10.2217/dmt.12.73 · Cited by 4
Exercise: It Isn't Just Child's Play When it Comes to Managing Type 1 Diabetes
Laffel, L. M. (2010) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2010.07.061 · Cited by 3
Differential effects of insulin induced hypoglycaemia upon redox balance in distinct rat brain areas
Dasgupta, A., Pal, M., Ghosh, T., Roy, U. K., Konar, S., Biswas, S., & Maity, C. (2013) · Oriental Pharmacy and Experimental Medicine · doi:10.1007/s13596-013-0111-9 · Cited by 6
“Hypoglycaemia has been a major limiting factor in maintaining a good glycemic control in DM as intensive insulin therapy increases the risk of iatrogenic hypoglycaemia (Cryer 2002).”
BackgroundPerioperative Glucose Management
Wei, N., & Wexler, D. J. (2012) · Hospital Medicine Clinics · doi:10.1016/j.ehmc.2012.05.002 · Cited by 2
“Hypoglycemia is a real risk in hospitalized patients, especially those treated with insulin, and is often the limiting factor in achieving adequate glycemic management (22).”
Background
Metadata
- Authors
- Cryer, P.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Cryer, P.
- Venue
- Diabetologia
- Published
- 2002-06
- Volume
- 45
- Issue
- 7
- Pages
- 937-948
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2124282046
- Semantic Scholar
- ebdcc733bdd208ee1005932d38511abefb8034d6
- Cited by
- 794
- References
- 58
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 11 · 2023: 15 · 2022: 16 · 2021: 22 · 2020: 18 · 2019: 24 · 2018: 39 · 2017: 49 · 2016: 32 · 2015: 60 · 2014: 65 · 2013: 66 · 2012: 53
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020579-35)
- National Institute of Diabetes and Digestive and Kidney Diseases (R37DK027085, P60-DK20579, R37-DK27085, T32 DK07120, T32DK007120)
- National Center for Research Resources (M01-RR00036, M01RR000036)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, hypoglycemia unawareness, glucose counterregulation, insulin excess, epinephrine response, glucagon response, type 1 diabetes, type 2 diabetes, glycemic control
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Epinephrine, Glucagon, Humans, Hypoglycemia, Insulin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.